Upstream Bio, Inc. (UPB)
| Market Cap | 517.53M |
| Revenue (ttm) | 2.85M |
| Net Income (ttm) | -143.44M |
| Shares Out | 54.42M |
| EPS (ttm) | -2.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 474,584 |
| Open | 9.32 |
| Previous Close | 9.29 |
| Day's Range | 9.28 - 9.65 |
| 52-Week Range | 7.25 - 33.68 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 37.67 (+296.11%) |
| Earnings Date | May 6, 2026 |
About UPB
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts. [Read more]
Financial Performance
In 2025, Upstream Bio's revenue was $2.85 million, an increase of 20.42% compared to the previous year's $2.37 million. Losses were -$143.44 million, 87.8% more than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for UPB stock is "Buy." The 12-month stock price target is $37.67, which is an increase of 296.11% from the latest price.
News
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirat...
Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data
The company reported a cash position of $341.5 million, expected to fund planned operations through 2027.
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP – – Company...
Upstream Bio Transcript: Leerink Global Healthcare Conference 2026
Verekitug demonstrated strong efficacy and quarterly dosing in phase II asthma trials, with plans to start phase III in severe asthma and CRSwNP by early next year. The COPD program is over 60% enrolled, and device development is progressing in parallel. Cash runway extends through 2027.
Upstream Bio Transcript: TD Cowen 46th Annual Health Care Conference
Verekitug demonstrated strong efficacy and safety in phase II trials for asthma and CRSwNP, with quarterly dosing matching or exceeding competitors. Phase III trials are planned for year-end, with advanced manufacturing and regulatory preparations supporting a rapid path to market.
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of - 1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provide...
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
– New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session –
Upstream Bio to Participate in Upcoming March Investor Conferences
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirator...
Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns
Upstream Bio Inc. (NASDAQ: UPB) shares are trading lower during Friday's session as the stock reacts to recent developments in its clinical trials.
Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts
The stock gave up its gains and is falling, probably on profit booking.
Upstream Bio Transcript: Study result
VALIANT phase II results show verekitug significantly reduced asthma exacerbations and improved lung function and biomarkers at both 12- and 24-week dosing intervals, with a favorable safety profile. These findings support advancing to phase III trials in severe asthma and CRSwNP.
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing –
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
– Webcast to be held Wednesday, February 11, 2026, at 8:00 a.m. ET – – Webcast to be held Wednesday, February 11, 2026, at 8:00 a.m. ET –
Upstream Bio Transcript: 44th Annual J.P. Morgan Healthcare Conference
Verekitug, a TSLP receptor-targeting biologic, shows strong efficacy and safety in CRS with NP and is advancing in severe asthma and COPD. Upcoming phase II asthma data will guide phase III plans, with a focus on infrequent dosing and broad patient reach.
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirator...
Upstream Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference
Verekitug’s phase II data in CRS with NP demonstrated strong efficacy and extended dosing, supporting rapid advancement to phase III trials in both CRS and severe asthma. The molecule’s unique receptor targeting and durability set it apart from competitors.
Upstream Bio Transcript: Piper Sandler 37th Annual Healthcare Conference
VALIANT asthma study data is expected in Q1 2026, with robust efficacy benchmarks and a focus on extended dosing intervals. Plans include simultaneous Phase 3 trials for asthma and sinusitis, leveraging verekitug's high potency and broad patient eligibility.
Upstream Bio to Participate in Upcoming December Investor Conferences
WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirator...
Upstream Bio Transcript: TD Cowen Immunology and Inflammation Summit
Positive phase 2 results in CRSwNP and robust pharmacodynamic data support extended dosing intervals and differentiation from competitors. Phase 2 asthma data are expected in Q1, with phase 3 programs for both indications to follow after data review and regulatory input.
Upstream Bio Transcript: Stifel 2025 Healthcare Conference
Verekitug, a potent TSLP receptor-targeting antibody, demonstrated robust efficacy and safety in phase II CRSwNP trials, with infrequent dosing and strong biomarker suppression. Upcoming severe asthma and COPD data may further support its differentiated profile and commercial potential.
Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress
– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary endp...
Upstream Bio to Participate in Upcoming November Investor Conferences
WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirator...
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress
– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodi...
Upstream Bio Transcript: Stifel Virtual Immunology and Inflammation Forum
Viraqita, a TSLP receptor antagonist, shows strong phase 2 efficacy in chronic rhinosinusitis with nasal polyps, matching or exceeding key competitors with less frequent dosing. Upcoming asthma data may further validate its unique pharmacology and broad potential.
Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirato...